hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06361459 id: NL83858.058.12 briefTitle: Stop Smoking in Spine Surgery overallStatus: RECRUITING date: 2023-07-06 date: 2026-06-30 date: 2026-12-31 date: 2024-04-11 date: 2024-04-11 name: Leiden University Medical Center class: OTHER name: Medical Center Haaglanden name: Haga Hospital name: Alrijne Hospital name: Spaarne Gasthuis briefSummary: Patients that are subjected to a medium complex surgical intervention in neck (posterior) or lumbar spine (posterior) with instrumentation are motivated to stop smoking. The outcome data of patients that stop and that continue smoking will be compared. A group of non smokers is evaluated as a control group. Particularly clinical outcome is evaluated, as well as radiological outcome. conditions: Smoking Cessation studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: three study groups: group that does not smoke, group that smokes and stops, group that smokes and does not stop primaryPurpose: TREATMENT masking: NONE count: 210 type: ESTIMATED name: Stop smoking measure: ODI or NDI measure: VAS leg or arm pain measure: HADS measure: EuroQol measure: perceived recovery measure: radiological evaluation for fusion sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Leiden University Medical Centre status: RECRUITING city: Leiden state: Zuid Holland zip: 2300RC country: Netherlands name: carmen vleggeert-lankamp, MD MSc PhD role: CONTACT phone: +31630925428 email: cvleggeert@lumc.nl lat: 52.15833 lon: 4.49306 hasResults: False
nctId: NCT06361446 id: 023098816 briefTitle: Zonisamide Versus Propranolol in Migraine overallStatus: RECRUITING date: 2024-03-29 date: 2025-03-30 date: 2025-04-20 date: 2024-04-11 date: 2024-04-23 name: Kafrelsheikh University class: OTHER briefSummary: Investigators aim to compare the effect of zonisamide versus propranolol in migraine by assessing the absolute reduction in MMD in each group, the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency conditions: Migraine studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: We will assess The number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency. HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: An independent statistician generated a blocked randomization sequence using computer-generated random numbers; participants received either zonisamide and acetaminophen or propranolol and acetaminophen from a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 600 labels for each drug labeled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 600. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrollment numbers starting from 1, which were mentioned in their files. Files with the same number as the patient enrolment number were opened and the patients were assigned to receive drugs A or B. Drug A included zonisamide and acetaminophen, and Drug B included propranolol and acetaminophen. The statistical analysis was performed by an independent statistician who did not know the treatment protocol of groups A or B. whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 600 type: ESTIMATED name: Zonisamide 50 MG name: Propranolol measure: The change in migraine days per 28 days measure: The total number of migraine days after three months of treatment measure: The percentage of patients who achieved ≥ 50% reduction in the monthly migraine days frequency compared to the baseline frequency. measure: HIT-6 score absolute change in each group after three months of treatment measure: The safety of lacosamide was evaluated by monitoring treatment-emergent adverse events (TEAE) for three months. sex: ALL minimumAge: 10 Years maximumAge: 55 Years stdAges: CHILD stdAges: ADULT facility: Kafr Elsheikh University Hospital status: RECRUITING city: Kafr Ash Shaykh zip: 33511 country: Egypt name: mohamed G. Zeinhom, MD role: CONTACT phone: 2001009606828 email: mohamed_gomaa@med.kfs.edu.eg lat: 31.11174 lon: 30.93991 hasResults: False
nctId: NCT06361433 id: R5-11 briefTitle: Intracerebral Transplantation of Autologous MSC Combined With Scaffold Product for Chronic Intracerebral Hemorrhage acronym: RAINBOW-Hx overallStatus: RECRUITING date: 2023-12-01 date: 2026-02 date: 2026-02 date: 2024-04-11 date: 2024-04-11 name: Hokkaido University Hospital class: OTHER name: Japan Agency for Medical Research and Development briefSummary: The goal of this clinical trial is to test intracerebral transplantation of stem cell product in patient with chronic intracerebral hemorrhage. The main questions aims to answer are:
* The efficacy of the product conditions: Intracerebral Hemorrhage studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 8 type: ESTIMATED name: HUFF-01 measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 measure: Change in mRS examination measure: Change in NIHSS examination measure: Change in FIM examination measure: Change in Fugl-Myer examination measure: Change in Barthal index examination measure: Change in FDG-PET examination measure: Change in IMZ-SPECT examination sex: ALL minimumAge: 20 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hokkaido University Hospital status: RECRUITING city: Sapporo state: Hokkaido zip: 0608638 country: Japan name: Masahito Kawabori role: CONTACT phone: +81117065987 email: masahitokawabori@yahoo.co.jp lat: 43.06667 lon: 141.35 hasResults: False
nctId: NCT06361420 id: 2023YF051-01 briefTitle: Driving Pressure-guided Lung Protective Ventilation acronym: DPV overallStatus: RECRUITING date: 2024-01-26 date: 2024-12-30 date: 2025-03-31 date: 2024-04-11 date: 2024-04-11 name: Yong Lin, PhD class: OTHER briefSummary: The study, named as "The Efficacy of Driving Pressure-guided Lung Protective Ventilation in Surgical Repair of Acute Type A Aortic Dissection: an open-label, randomized control clinical trial", aims to investigate whether driving pressure-guided lung protective ventilation can reduce postoperative oxygenation function in patients who have undergone surgical repair of acute type A aortic dissection. The primary outcomes is the incidence of postoperative hypoxemia (a partial pressure of arterial oxygen to inspiratory oxygen fraction ratio less than 300 mm Hg or a peripheral blood oxygen saturation less than 93% at any concentration of inspiratory oxygen) within 7 days after the surgery. conditions: Hypoxemia conditions: Ventilator Lung studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: open, randomised control trial primaryPurpose: PREVENTION masking: NONE count: 43 type: ESTIMATED name: Driving pressure-guided positive end expiratory pressure name: Optimal oxygenation-guided positive end expiratory pressure name: Ventilation strategy name: Management of hypoxemia measure: The incidence of postoperative hypoxemia measure: The trend of perioperative oxygenation function measure: Postoperative pulmonary complications except hypoxemia measure: Early/late death measure: Vasoactive-inotropic score at the end of surgery measure: Postoperative adverse cardiovascular events measure: Length of stay in intensive care unit measure: Ventilation assistance time measure: Postoperative extrapulmonary complications sex: ALL minimumAge: 14 Years maximumAge: 70 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Fujian medical university union hospital status: RECRUITING city: Fuzhou state: Fujian zip: 350001 country: China name: Yong Lin, MD role: CONTACT phone: 13805064575 email: birdman1983@163.com lat: 26.06139 lon: 119.30611 hasResults: False
nctId: NCT06361407 id: 2023-A02464-41 briefTitle: Sensory and Cognitive Predictions, and Their Disruptions in Schizophrenia acronym: SensoSchiz overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-04-30 date: 2028-02-28 date: 2024-04-11 date: 2024-04-11 name: Centre Psychothérapique de Nancy class: OTHER name: Institut National de la Santé Et de la Recherche Médicale, France briefSummary: Disturbances in the sense of self and time could play an important role in the development of psychotic symptoms. Previous work has shown that patients have difficulty preparing to process information on the scale of a second, but are abnormally disturbed by slightly asynchronous information on the millisecond scale. In both cases, the anomalies could explain the patients' unusual experience of time. The hypothesis in neurotypical patients is that small delays or asynchronies asynchronies are treated as irrelevant information and ignored and ignored, whereas in patients suffering from schizophrenia they would disrupt the flow of time. This hypothesis is tested with a new visual illusion. conditions: Schizophrenia conditions: Sensory Processing Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Individuals with schizophrenia will be tested in parallel with neurotypicals primaryPurpose: BASIC_SCIENCE masking: NONE maskingDescription: The group will be masked at the stage of data analysis. It cannot be masked at the prior stages count: 68 type: ESTIMATED name: Illusion task measure: Effect of a millisecond-level trajectory perturbation measure: Baseline rate of illusion measure: Effect of a rebound (top-down, conscious influence) sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06361394 id: CORPFIN0021 briefTitle: The Impacts of Mindfulness on Psychological Wellbeing Among Nursing Students overallStatus: RECRUITING date: 2024-02-20 date: 2024-07-25 date: 2025-08-31 date: 2024-04-11 date: 2024-04-11 name: Chang Gung University of Science and Technology class: OTHER briefSummary: The aims of this study are to develop a mindfulness-based course for nursing students. As well as, to verify the effects on psychological well-being (mindfulness, stress, and anxiety) and nursing professional related competences (empathy, clinical practicum stress, nursing competency) among nursing students. conditions: Students studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The experimental group will enroll in the elective course named "Mindfulness and Happiness," which will consist of 2 hours every week for a continuous period of 18 weeks. The comparison group will not participate in this course. primaryPurpose: TREATMENT masking: NONE count: 240 type: ESTIMATED name: mindfulness course measure: perceived stress at baseline measure: perceived stress at T0 measure: perceived stress at T1 measure: perceived stress at T2 measure: anxiety disorder at baseline measure: anxiety disorder at T0 measure: anxiety disorder at T1 measure: anxiety disorder at T2 measure: mindful attention awareness at baseline measure: mindful attention awareness at T0 measure: mindful attention awareness at T1 measure: mindful attention awareness at T2 measure: empathy at baseline measure: empathy at at T0 measure: empathy at at T1 measure: empathy at at T2 measure: practicum stress at T1 measure: practicum stress at T2 measure: Nursing Competence at T1 measure: Nursing Competence at T2 sex: ALL minimumAge: 20 Years maximumAge: 50 Years stdAges: ADULT facility: Ya-Chu Hsiao status: RECRUITING city: Taoyuan City state: N/A = Not Applicable zip: 333 03 country: Taiwan name: ya-chu hsiao, EdD role: CONTACT phone: +886939740890 email: yjshiao@mail.cgust.edu.tw lat: 24.95233 lon: 121.20193 hasResults: False
nctId: NCT06361381 id: 24-01-281 briefTitle: The Combined Effect of TENS and TaVNS on Pressure and Heat Pain Thresholds in Pain-Free Subjects overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-06 date: 2024-12 date: 2024-04-11 date: 2024-04-11 name: University of Hartford class: OTHER briefSummary: Transcutaneous electrical nerve stimulation (TENS) is a non-invasive modality that utilizes electrical currents to modulate pain in populations with acute and chronic pain. TENS has been demonstrated to produce hypoalgesic effects in postoperative pain, fibromyalgia, knee osteoarthritis, and healthy subjects. Transcutaneous auricular vagus nerve stimulation (TaVNS) is a non-invasive modality that modulates the vagus nerve by stimulating its auricular branches. The effects of the combination of TENS and TaVNS on producing an analgesic response have not been studied. Considering that TENS and TaVNS both stimulate similar analgesic pathways but through different means of activation, the investigators can hypothesize that a combination of both methods can produce a more pronounced analgesic response. Therefore, the objective of this study is to assess the hypoalgesic effect of a combination of TENS and TaVNS in pain-free subjects.
The study will be a simple crossover design conducted at the University of Hartford. Subjects will be recruited from the University of Hartford population via oral communication, digital flyers, and posters on campus. Thirty participants will undergo two sessions in a crossover manner with one week in between. During one session, the participants will receive TENS with active TaVNS and the other session will be a placebo procedure (TENS with placebo TaVNS). The order of these sessions will be randomized. Importantly, the pressure pain threshold (PPT) and heat pain threshold (HPT) assessors will be blinded to the treatment category. For active TaVNS, a frequency of 25 Hz will be applied with a pulse duration of 200 µs. For placebo TaVNS, the intensity will be increased to a sensory level and then decreased to 0 mA. High frequency TENS of 100Hz will be applied in both sessions, with a pulse duration of 200 µsec, asymmetrical biphasic square waveform, and intensity of maximal tolerance without pain. TENS and TaVNS will be turned on for 30 minutes after a baseline measurement of outcomes. TENS and TaVNS will then be turned off, but the electrodes will remain on until completion of post-treatment assessment. Pressure pain threshold, heat pain threshold, blood pressure, oxygen saturation and heart rate will be tested 4 times: Once pre-intervention, once during intervention, once immediately after the intervention and once 15 minutes post-intervention. conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Active Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS) name: Placebo Transcutaneous Auricular Vagus Nerve Stimulation (TaVNS) name: Transcutaneous Electrical Nerve Stimulation measure: Pressure Pain Threshold measure: Heat Pain Threshold measure: Heart rate measure: Oxygen saturation measure: Blood pressure sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: University of Hartford city: West Hartford state: Connecticut zip: 06117 country: United States lat: 41.76204 lon: -72.74204 hasResults: False
nctId: NCT06361368 id: NYCU112174AF briefTitle: Efficacy Assessment of Probiotics in Improving Sleep Indices overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-03 date: 2026-03 date: 2024-04-11 date: 2024-04-11 name: National Yang Ming University class: OTHER name: Bened Biomedical Co., Ltd. briefSummary: To determine whether PS150 (1) reduces insomnia symptoms, (2) improves sleep quality, (3) adjusts autonomic nervous system functioning, (4) reduces the severity of anxiety and depressive symptoms, and (5) adjusts microbiome and endocrine functions. conditions: Insomnia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 140 type: ESTIMATED name: PS150 name: Placebo measure: Polysomnography (PSG) measure: Pittsburgh Sleep Quality Index (PSQI) measure: Insomnia Severity Index (ISI) measure: Beck Depression Inventory-Second Edition (BDI-II) measure: Beck Anxiety Inventory (BAI) measure: VAS-Sleep measure: Epworth Sleepiness Scale (ESS) measure: Standford Sleepiness Scale (SSS) measure: Visual Analogue Scale for gastrointestinal symptoms (VAS-GI) measure: Saliva Melatonin measure: Saliva Cortisol measure: Saliva IL-6 measure: Saliva Total Antioxidant Capacity (TAC) measure: Saliva Serotonin measure: Saliva GABA measure: Saliva Orexin measure: Urine 6-sulfatoxymelatonin measure: Urine Norepinephrine measure: Actigraphy measure: Sleep Diary sex: ALL minimumAge: 20 Years maximumAge: 60 Years stdAges: ADULT facility: Institute of Brain Science National Yang Ming Chiao Tung University city: Taipei zip: 112304 country: Taiwan name: Yu En Kuo, Master role: CONTACT phone: +886 975231262 email: iankuo1106@gmail.com lat: 25.04776 lon: 121.53185 hasResults: False
nctId: NCT06361355 id: CMAB807-I-002 briefTitle: Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy Volunteers overallStatus: RECRUITING date: 2023-11-02 date: 2024-04 date: 2024-06 date: 2024-04-11 date: 2024-04-11 name: Taizhou Mabtech Pharmaceutical Co.,Ltd class: INDUSTRY briefSummary: This is a randomized, double-blinded, parallel-controlled Phase I study of CMAB807 administered by subcutaneous injection. This study will characterize the pharmacokinetic, pharmacodynamics, safety and immunogenicity of CMAB807 Post-change in Manufacturing Site, versus Prolia #Denosumab# in healthy male subjects after a single dose conditions: Healthy Volunteers studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Biological: Post-change CMAB807, Prolia primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 132 type: ESTIMATED name: Post-change CMAB807 name: Prolia measure: Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time measure: Maximum Concentration of Denosumab measure: Time to Maximum Concentration of Denosumab measure: Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 3000 Hours measure: Half-time measure: Clearance Rate measure: Apparent Volume measure: Serum type 1 C-telopeptide (CTX1) measure: anti-drug antibodies(ADA) measure: Neutralization antibodies(Nab) measure: Percentage and Severity of Participants with Adverse Events sex: MALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: The Second Hospital of Anhui Medical University status: RECRUITING city: Hefei state: Anhui country: China name: Hu Wei, Doctor role: CONTACT phone: 0551-65997164 email: hwgcp@ayefy.com lat: 31.86389 lon: 117.28083 hasResults: False
nctId: NCT06361342 id: 23-003633 briefTitle: Smartphones Aggravating Anxiety Symptoms overallStatus: ENROLLING_BY_INVITATION date: 2024-03-08 date: 2025-03 date: 2025-03 date: 2024-04-11 date: 2024-04-11 name: Mayo Clinic class: OTHER briefSummary: The goal of this study is to assess if excessive use of smartphone apps of social media can impact a person's mental health. The study is aimed at improving the usage of smartphones which might help improve the mental health of patients. The goal is not to discourage the use of smartphones but instead to utilize smartphones in a way that they do not impact lives. conditions: Anxiety studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: General decrease in smartphone use name: Avoiding Social Media Apps measure: Change in anxiety measure: Change in depression sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic Minnesota city: Rochester state: Minnesota zip: 55905 country: United States lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06361329 id: 20240030C briefTitle: Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL overallStatus: RECRUITING date: 2024-04 date: 2026-03-31 date: 2027-03-31 date: 2024-04-11 date: 2024-04-29 name: First Affiliated Hospital of Zhejiang University class: OTHER briefSummary: ETP-ALL is a subtype of T-cell acute lymphoblastic leukemia (T-ALL) with poor outcomes and prognosis. Effective induction therapy is crucial in improving the treatment effect. Based on our laboratory research and clinical practice, the venetoclax plus HAG regimen shows promising efficacy in treating ETP-ALL. Therefore, we plan to conduct a prospective, multicenter Phase III clinical study to evaluate the efficacy of the venetoclax plus HAG regimen in treating newly diagnosed ETP-ALL patients. conditions: ETP-ALL studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 81 type: ESTIMATED name: Homoharringtonine name: venetoclax name: Cytarabine name: G-CSF name: Vindesine name: Daunorubicin name: cyclophosphamide name: Dexamethasone name: L-ASP measure: 1-year EFS measure: CR/CRi measure: OS measure: MRD measure: Safety of induction therapy sex: ALL minimumAge: 14 Years maximumAge: 75 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital, College of Medicine, Zhejiang University status: RECRUITING city: Hangzhou state: Zhejiang zip: 310003 country: China name: Jie Jin, PhD&MD role: CONTACT phone: 13705716779 email: jiej0503@163.com lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06361316 id: CSPC-DEY-PC-JS01 briefTitle: Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer overallStatus: RECRUITING date: 2024-04-08 date: 2025-03-25 date: 2028-07-31 date: 2024-04-11 date: 2024-04-11 name: Kuirong Jiang class: OTHER name: CSPC Ouyi Pharmaceutical Co., Ltd. briefSummary: The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer. conditions: Pancreatic Cancer conditions: Adjuvant Therapy studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 53 type: ESTIMATED name: Irinotecan liposome injection measure: Disease Free Survival, DFS measure: Adverse events (aes) were determined and graded according to NCI-CTCAE version 5.0, and evaluated by the overall incidence of AE, the incidence of AE grade 3 or above, and the incidence of SAE measure: Overall Survival, OS measure: Quality of life, QOL measure: The results were presented in terms of the proportion of patients who completed 6 months of chemotherapy measure: he results were presented in terms of the proportion of patients who were replaced with 5-FU/LV due to Tegafur intolerance sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: FirstNanjingMU status: RECRUITING city: Nanjing state: Jiangsu zip: 025 country: China name: KuiRong Jiang, archiater role: CONTACT phone: 15312995688 email: Jiangkuirong@163.com name: Min Tu, associate doctor role: SUB_INVESTIGATOR lat: 32.06167 lon: 118.77778 hasResults: False